Table 2 Clinical characteristics and... | American Society of Hematology

Table 2

Clinical characteristics and treatment of MPN before transformation

	n	Thrombotic events, (%)*	Antiaggregating therapy or anticoagulant therapy, n (%)*	HU, n (%)*	Median duration of HU, mo	Pipobroman, n (%)*	Median duration of pipobroman, mo	P32 or alkylating agent, n (%)	Median time to progression, mo
ET	21	3 (14)	11 (52)	14 (66)	54	6 (29)	66		70
PV	21	8 (38)	7 (33)	16 (76)	60	14 (66)	60	4 (19)	154
PMF	7	1 (14)	1 (14)	1 (14)	6				19
MPNu†	5	1 (20)	2 (40)	3 (60)	12				19

	n	Thrombotic events, (%)*	Antiaggregating therapy or anticoagulant therapy, n (%)*	HU, n (%)*	Median duration of HU, mo	Pipobroman, n (%)*	Median duration of pipobroman, mo	P32 or alkylating agent, n (%)	Median time to progression, mo
ET	21	3 (14)	11 (52)	14 (66)	54	6 (29)	66		70
PV	21	8 (38)	7 (33)	16 (76)	60	14 (66)	60	4 (19)	154
PMF	7	1 (14)	1 (14)	1 (14)	6				19
MPNu†	5	1 (20)	2 (40)	3 (60)	12				19

HU indicates hydroxyurea; ET, essential thrombocythemia; PV, polycythemia vera; PMF, primary myelofibrosis; and MPNu, myeloproliferative neoplasm unclassified;

During MPN phase.

†

Three of the patients with MPNu received imatinib.

View Large

This Feature Is Available To Subscribers Only